Tag Archives: Phil Nadeau

Kezar Life Sciences Inc (KZR) Received its Third Buy in a Row

After William Blair and Wells Fargo gave Kezar Life Sciences Inc (NASDAQ: KZR) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Phil Nadeau maintained a Buy rating on Kezar Life Sciences

Analysts Offer Insights on Healthcare Companies: Portola Pharma (NASDAQ: PTLA), Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) and Loxo Oncology (NASDAQ: LOXO)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Portola Pharma (NASDAQ:PTLA), Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) and Loxo Oncology (NASDAQ:LOXO) with bullish sentiments. Portola Pharma (PTLA) In a report released today,

Cowen & Co. Keeps Their Buy Rating on Acorda Therapeutics (ACOR)

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Acorda Therapeutics (NASDAQ: ACOR) today and set a price target of $30. The company’s shares opened today at $27.50. According to TipRanks.com, Nadeau is a 5-star analyst with an

Apellis Pharmaceuticals Inc Gets a Buy Rating from Cowen & Co.

In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Buy rating on Apellis Pharmaceuticals Inc (NASDAQ: APLS), with a price target of $40. The company’s shares opened today at $17.26. According to TipRanks.com, Nadeau is a

Cowen & Co. Believes Biogen Inc (NASDAQ: BIIB) Won’t Stop Here

Cowen & Co. analyst Phil Nadeau assigned a Buy rating to Biogen Inc (NASDAQ: BIIB) today and set a price target of $408. The company’s shares opened today at $380, close to its 52-week high of $383. According to TipRanks.com,

Cowen & Co. Assigns a Buy Rating on Syros Pharmaceuticals

In a report released today, Phil Nadeau from Cowen & Co. assigned a Buy rating to Syros Pharmaceuticals (NASDAQ: SYRS). The company’s shares opened today at $12.68. According to TipRanks.com, Nadeau is a 5-star analyst with an average return of